🔎 Trials Near Me

Home › Acute Biphenotypic Leukemia › Oregon

Acute Biphenotypic Leukemia clinical trials in Oregon

6 studies for Acute Biphenotypic Leukemia are looking for participants at sites in Oregon.

Cities in Oregon

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Oregon Health & Science University, Portland
RecruitingPhase 1/2
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Oregon Health & Science University, Portland
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.